ClinicalTrials.gg
RecruitingNCT06780098Updated Nov 13, 2026

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

A Phase 2 interventional study of R-DXD and I-DXD in Lung Neoplasm, sponsored by Merck Sharp & Dohme LLC. Recruiting at 46 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 13, 2026Interventions changed5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Lung Neoplasms by Merck & Co., Inc — 4 open to participants now, 8 under way, 3 of them phase 3. Lung Neoplasms · Merck & Co., Inc.

Planned enrollment
7th of 12
144 · median 188
Started
2025
with 2 others
Phase 2
3 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Lung Neoplasms by Merck & Co., Inc, this one is the 7th largest by planned enrollment, is one of 3 that started in 2025, is one of 3 in phase 2, and was the 10th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

4 of the 12 studies in Lung Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lung Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body.

Standard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may not work or may stop working to treat metastatic squamous NSCLC.

Researchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells.

The main goals of this study are to learn about:

  • The cancer response to the study treatments compared to chemotherapy
  • The safety of the study treatments and if people tolerate them

This study is one of the substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Read the detailed description

The master screening protocol is MK-3475-U01 (KEYMAKER-U01) - NCT04165798

03

Conditions studied

  • Lung Neoplasm

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • or cytologically confirmed diagnosis of Stage IV squamous non-small cell lung cancer (NSCLC)
  • Has documented disease progression per 1.1 (RECIST 1.1), as assessed by investigator after receiving an anti-programmed cell death protein 1 ()/programmed cell death ligand 1 (PD-L1) treatment and platinum-based chemotherapy for Stage IV disease
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
  • Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • Has uncontrolled or significant cardiovascular disorder
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months, severe asthma, severe , restrictive lung disease, pleural effusion, etc), or any , connective tissue, or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc), or prior pneumonectomy
  • Participants who have adverse events (AEs) (other than alopecia) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline
  • Has corneal disease
  • Has previously received docetaxel as monotherapy or in combination with other therapies
  • Known additional that is progressing or has required active treatment within the past 3 years
  • Has known untreated central nervous system (CNS) and/or carcinomatous meningitis
  • Evidence of any
  • Has one or more of the following indicators of interstitial lung disease (ILD)/pneumonitis: any history of ILD/pneumonitis irrespective of use (except for a history of radiation pneumonitis that did not require steroids), current diagnosis of ILD, clinical or radiographic suspicion of ILD
  • Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • Active infection requiring systemic therapy
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Active inflammatory bowel disease requiring medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
  • Known history of, or active, neurologic paraneoplastic syndrome
  • History of allogeneic tissue/solid organ transplant
  • Has not adequately recovered from major surgery or have ongoing surgical complications
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Arm 1: Raludotatug deruxtecan (R-DXD)

    Participants receive 5.6 mg/kg of R-DXD, every 3 weeks (Q3W) (Day 1 of every 21-day cycle) via intravenous (IV) infusion until progressive disease (PD) or discontinuation.

    Biological: R-DXD · Drug: Rescue Medications

  • Experimental
    Arm 2: Ifinatamab deruxtecan (I-DXD) High Dose

    Participants receive 12 mg/kg of I-DXD, Q3W (Day 1 of every 21-day cycle) via IV infusion until PD or discontinuation.

    Biological: I-DXD · Drug: Rescue Medications

  • Experimental
    Arm 3: I-DXD Low Dose

    Participants receive 8 mg/kg of I-DXD, Q3W (Day 1 of every 21-day cycle) via IV infusion until PD or discontinuation.

    Biological: I-DXD · Drug: Rescue Medications

  • Active comparator
    Arm 4: Docetaxel

    Participants receive 75 mg/m\^2 of Docetaxel, Q3W (Day 1 of every 21-day cycle) via IV infusion until PD or discontinuation.

    Drug: Docetaxel · Drug: Rescue Medication

Interventions

  • BiologicalR-DXD

    IV Infusion

    Also known as: Raludotatug deruxtecan, MK-5909, DS-6000a

  • BiologicalI-DXD

    IV Infusion

    Also known as: Ifinatamab deruxtecan, MK-2400, DS-7300a

  • IV Infusion

    Also known as: Taxotere®

  • DrugRescue Medications

    Participants receive rescue medications consisting of a combination regimen to include corticosteroids with a 5-hydroxytryptamine subtype 3 receptor antagonist and/or a neurokinin-1 receptor antagonist, all per approved product label and following institutional standards or local guidelines.

  • DrugRescue Medication

    Participants are premedicated with corticosteroids per approved product label and following institutional standards or local guidelines.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) as assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). ORR will be assessed by Blinded Independent Central Review (BICR). The percentage of participants who experience CR or PR as assessed by the investigator will be presented.

    Time frame: Up to approximately 81 months

  2. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 81 months

  3. Number of participants who discontinue study intervention due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 81 months

Secondary outcomes

  1. Duration of Response (DOR)

    For participants who demonstrate a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to approximately 81 months

  2. Progression-free Survival (PFS)

    PFS is defined as the time from randomization to the first documented PD or death due to any cause, whichever occurs first as assessed by (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to approximately 81 months

  3. Overall Survival (OS)

    OS is defined as time from randomization to death due to any cause.

    Time frame: Up to approximately 81 months

07

Study locations

46 of 46 sites recruiting
  • University of Kentucky Chandler Medical Center ( Site 0019)
    Lexington, Kentucky 40536-0293, United States
    Recruiting
    • Study Coordinator · Contact859-257-1000
  • MedStar Franklin Square Medical Center ( Site 0033)
    Baltimore, Maryland 21237, United States
    Recruiting
    • Study Coordinator · Contact443-777-7147
  • Texas Oncology - DFW ( Site 8003)
    Dallas, Texas 75246-2046, United States
    Recruiting
    • Study Coordinator · Contact214-370-1067
  • Virginia Cancer Specialists (VCS) ( Site 0408)
    Fairfax, Virginia 22031, United States
    Recruiting
    • Study Coordinator · Contact703-280-5390
  • Centro de Estudios Clínicos SAGA ( Site 0161)
    Santiago, Region M. de Santiago 7500653, Chile
    Recruiting
    • Study Coordinator · Contact+56991612199
  • Fundación Arturo López Pérez ( Site 0160)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56227128000
  • Bradfordhill ( Site 0162)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56229490970
  • Beijing Cancer Hospital ( Site 0301)
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Study Coordinator · Contact010-88121122
  • Chongqing University Cancer Hospital ( Site 0304)
    Chongqing, Chongqing Municipality 400030, China
    Recruiting
    • Study Coordinator · Contact+86023-65311341
  • Fujian Provincial Cancer Hospital ( Site 0310)
    Fuzhou, Fujian 350014, China
    Recruiting
    • Study Coordinator · Contact0591-83660063
  • Guangxi Medical University Cancer Hospital ( Site 0303)
    Nanning, Guangxi 530201, China
    Recruiting
    • Study Coordinator · Contact0771-5323175
  • Henan Cancer Hospital ( Site 0311)
    Zhengzhou, Henan 450000, China
    Recruiting
    • Study Coordinator · Contact+8613837174273
  • Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 0309)
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Study Coordinator · Contact+86021-65115006
  • Shanghai Chest Hospital ( Site 0308)
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
    • Study Coordinator · Contact021-63846590
  • Shanghai Pulmonary Hospital ( Site 0300)
    Shanghai, Shanghai Municipality 200433, China
    Recruiting
    • Study Coordinator · Contact021-65115006
  • UniversitaetsklInikum Tuebingen ( Site 0192)
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
    • Study Coordinator · Contact+4970712982795
  • Charite-Universitaetsmedizin Berlin ( Site 0191)
    Berlin, 13353, Germany
    Recruiting
    • Study Coordinator · Contact+49 30 450 553 044
  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)
    Athens, Attica 115 27, Greece
    Recruiting
    • Study Coordinator · Contact0030 2107700220
  • F. THERAPIS GENERAL ( Site 0206)
    Athens, Attica 116 34, Greece
    Recruiting
    • Study Coordinator · Contact+302107291111
  • European Interbalkan Medical Center-Oncology Department ( Site 0205)
    Thessaloniki, 570 01, Greece
    Recruiting
    • Study Coordinator · Contact0030 2310400213
  • Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 0063)
    Kecskemét, Bács-Kiskun county 6000, Hungary
    Recruiting
    • Study Coordinator · Contact+3676516700
  • Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)
    Győr, Győr-Moson-Sopron 9024, Hungary
    Recruiting
    • Study Coordinator · Contact+3696507900
  • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
    Recruiting
    • Study Coordinator · Contact+3656503603
  • Rambam Health Care Campus ( Site 0076)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact+972 47776234
  • Shaare Zedek Medical Center ( Site 0075)
    Jerusalem, 9103102, Israel
    Recruiting
    • Study Coordinator · Contact+972-2-6555768
  • Meir Medical Center ( Site 0071)
    Kfar Saba, 4428164, Israel
    Recruiting
    • Study Coordinator · Contact+97297472414
  • Rabin Medical Center ( Site 0074)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+97239378101
  • Sheba Medical Center ( Site 0070)
    Ramat Gan, 5265601, Israel
    Recruiting
    • Study Coordinator · Contact+97235307032
  • Sourasky Medical Center ( Site 0077)
    Tel Aviv, 6423906, Israel
    Recruiting
    • Study Coordinator · Contact+972-3-6973082
  • Azienda Ospedaliera Universitaria Careggi ( Site 0173)
    Florence, 50134, Italy
    Recruiting
    • Study Coordinator · Contact+393209225506
  • IRCCS Ospedale San Raffaele ( Site 0171)
    Milan, 20132, Italy
    Recruiting
    • Study Coordinator · Contact+390223903829
  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)
    Milan, 20133, Italy
    Recruiting
    • Study Coordinator · Contact390223902190
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)
    Roma, 00168, Italy
    Recruiting
    • Study Coordinator · Contact+390630156318
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0153)
    Poznan, Greater Poland Voivodeship 60-569, Poland
    Recruiting
    • Study Coordinator · Contact+48616654242
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
    • Study Coordinator · Contact+48225463066
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
    Gdansk, Pomeranian Voivodeship 80-214, Poland
    Recruiting
    • Study Coordinator · Contact+48585844466
  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0152)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
    Recruiting
    • Study Coordinator · Contact+48943488930
  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
    • Study Coordinator · Contact0034932607744
  • Hospital Clinic de Barcelona ( Site 0092)
    Barcelona, Catalonia 08036, Spain
    Recruiting
    • Study Coordinator · Contact34 932275402
  • Hospital Universitario Quiron Madrid ( Site 0091)
    Madrid, 28223, Spain
    Recruiting
    • Study Coordinator · Contact34914521987
  • Hospital Universitario Virgen Macarena ( Site 0094)
    Seville, 41009, Spain
    Recruiting
    • Study Coordinator · Contact+34 671560092
  • Ege Universitesi Hastanesi ( Site 0143)
    Izmir, İzmir 35100, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90 232 343 43 43
  • Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 0141)
    Adana, 01250, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+905353067506
  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0140)
    Ankara, 06230, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+90 312 305 43 36
  • Ankara Bilkent Şehir Hastanesi. ( Site 0142)
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+903125529999
  • Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0144)
    Istanbul, 34098, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+902124143000
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2032, 81 months after the start.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 81 months is above that.

Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
May 28, 2025
Primary completionEst.
Mar 2, 2032
CompletionEst.
Mar 2, 2032
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 4 sites removed
Show 5 added (1 Greece, 1 United States, 1 Chile, 1 Italy, 1 Spain)
  • F. THERAPIS GENERAL ( Site 0206) · Athens, Greece
  • Virginia Cancer Specialists (VCS) ( Site 0408) · Fairfax, United States
  • Fundación Arturo López Pérez ( Site 0160) · Santiago, Chile
  • IRCCS Ospedale San Raffaele ( Site 0171) · Milan, Italy
  • Hospital Clinic de Barcelona ( Site 0092) · Barcelona, Spain
Show 4 removed
  • EVANGELISMOS S.A ( Site 0206) · Athens, Greece
  • FALP ( Site 0160) · Santiago, Chile
  • Ospedale San Raffaele. ( Site 0171) · Milan, Italy
  • Hospital Clinic de Barcelona ( Site 0092) · Barcelona, Spain
across 3 updates, Sep 28, 2026 – Oct 7, 2026
Interventions
Arm changed Arm 2: Infinatamab deruxtecan (I-DXD) High Dose→Arm 2: Ifinatamab deruxtecan (I-DXD) High Dose
Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 0309) · Nanjing, ChinaContact •••5910→•••5006
Oct 2, 2026
Show all 4 updates
  1. Nov 13, 2026
    Interventions Arm changed Arm 2: Infinatamab deruxtecan (I-DXD) High Dose→Arm 2: Ifinatamab deruxtecan (I-DXD) High Dose
    + 2 other changes: verification date and references
  2. Oct 7, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 Italy, 1 Spain)
    • IRCCS Ospedale San Raffaele ( Site 0171) · Milan, Italy
    • Hospital Clinic de Barcelona ( Site 0092) · Barcelona, Spain
    Show 2 removed
    • Ospedale San Raffaele. ( Site 0171) · Milan, Italy
    • Hospital Clinic de Barcelona ( Site 0092) · Barcelona, Spain
    + 1 other change: verification date
  3. Oct 2, 2026
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 Chile)
    • Virginia Cancer Specialists (VCS) ( Site 0408) · Fairfax, United States
    • Fundación Arturo López Pérez ( Site 0160) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 0160) · Santiago, Chile
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 0309) · Nanjing, ChinaContact •••5910→•••5006
  4. Sep 28, 2026
    1 site added, 1 site removed
    Show site
    • F. THERAPIS GENERAL ( Site 0206) · Athens, Greece
    Show 1 removed
    • EVANGELISMOS S.A ( Site 0206) · Athens, Greece

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06780098
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
May 28, 2025
Primary completion
Mar 2, 2032 (estimated)
Completion
Mar 2, 2032 (estimated)
Last update
Nov 13, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Raludotatug deruxtecan · Ifinatamab deruxtecan

Start the discussion